Drug-induced liver injury: Is it somehow foreseeable?

World Journal of Gastroenterology

Volumn 15, Issue 23, 2009, Pages 2817-2833

  Tarantino, Giovanni ^a   Di Minno, Matteo Nicola Dario ^a   Capone, Domenico ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Cytochrome P 450; Drug metabolism; Drug induced liver injury; Herbal remedies; Pharmacogenomics

Indexed keywords

ACEBUTOLOL; ACETYLSALICYLIC ACID; ADENOSINE TRIPHOSPHATE; ALLOPURINOL; AMIODARONE; ANABOLIC AGENT; ASPARAGINASE; AZATHIOPRINE; CAPTOPRIL; CARBAMAZEPINE; CARBIMAZOLE; CHLORPROMAZINE; CORTICOSTEROID; CYTOCHROME; DANAZOL; DANTROLENE; DILTIAZEM; IBUPROFEN; ISONIAZID; LAMOTRIGINE; METHOTREXATE; METHYLDOPA; NIMESULIDE; NITROFURANTOIN; ORAL CONTRACEPTIVE AGENT; PARACETAMOL; PHENYTOIN; SALICYLIC ACID DERIVATIVE; TERBINAFINE; UNINDEXED DRUG;

ACUTE DISEASE; ACUTE HEPATITIS; AGE; APOPTOSIS; BIOTRANSFORMATION; CALCIUM HOMEOSTASIS; CAUSAL ATTRIBUTION; CHOLESTATIC SYNDROME; CHRONIC LIVER DISEASE; CLINICAL FEATURE; CYTOPLASM; DIET; DIET SUPPLEMENTATION; DRUG BINDING; DRUG INDUCED DISEASE; DRUG INDUCED LIVER INJURY; DRUG USE; EDITORIAL; ELECTROLYTE DISTURBANCE; ETHICS; ETHNIC OR RACIAL ASPECTS; FATTY LIVER; FIBROSIS; GENDER; GENOTYPE; HEPATITIS; HERBAL MEDICINE; HUMAN; HYPERSENSITIVITY; IMMUNOPATHOLOGY; INFLAMMATION; LEGAL ASPECT; LIPID PEROXIDATION; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FAILURE; LIVER GRANULOMA; LIVER HISTOLOGY; LIVER TOXICITY; LIVER TUMOR; NUTRITIONAL STATUS; OXIDATIVE STRESS; PHENOTYPE; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN SYNTHESIS INHIBITION; RNA INTERFERENCE; VASCULAR DISEASE;

EID: 67651244726     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.15.2817     Document Type: Editorial

References (201)

1. Gunawan B, Kaplowitz N. Clinical perspectives on xenobiotic-induced hepatotoxicity. Drug Metab Rev 2004; 36: 301-312
2. Liu YT, Hao HP, Liu CX, Wang GJ, Xie HG. Drugs as CYP3A probes, inducers, and inhibitors. Drug Metab Rev 2007; 39: 699-721
3. Floby E, Briem S, Terelius Y, Sohlenius-Sternbeck AK. Use of a cocktail of probe substrates for drug-metabolizing enzymes for the assessment of the metabolic capacity of hepatocyte preparations. Xenobiotica 2004; 34: 949-959
4. Dixit V, Hariparsad N, Desai P, Unadkat JD. In vitro LCMS cocktail assays to simultaneously determine human cytochrome P450 activities. Biopharm Drug Dispos 2007; 28: 257-262
5. Jones JO, Diamond MI. Design and implementation of cell-based assays to model human disease. ACS Chem Biol 2007; 2: 718-724
6. Li J, Liu Y, Zhang JW, Wei H, Yang L. Characterization of hepatic drug-metabolizing activities of Bama miniature pigs (Sus scrofa domestica): comparison with human enzyme analogs. Comp Med 2006; 56: 286-290
7. Fujita K, Kamataki T. Genetically engineered bacterial cells co-expressing human cytochrome P450 with NADPH-cytochrome P450 reductase: prediction of metabolism and toxicity of drugs in humans. Drug Metab Pharmacokinet 2002; 17: 1-22
8. Meier Y, Cavallaro M, Roos M, Pauli-Magnus C, Folkers G, Meier PJ, Fattinger K. Incidence of drug-induced liver injury in medical inpatients. Eur J Clin Pharmacol 2005; 61: 135-143
9. Andrade RJ, Lucena MI, Fernandez MC, Pelaez G, Pachkoria K, Garcia-Ruiz E, Garcia-Munoz B, Gonzalez-Grande R, Pizarro A, Duran JA, Jimenez M, Rodrigo L, Romero-Gomez M, Navarro JM, Planas R, Costa J, Borras A, Soler A, Salmeron J, Martin-Vivaldi R. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129: 512-521
10. De Valle MB, Av Klinteberg V, Alem N, Olsson R, Bjornsson E. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Aliment Pharmacol Ther 2006; 24: 1187-1195
11. Marti L, Del Olmo JA, Tosca J, Ornia E, Garcia-Torres ML, Serra MA, Rodriguez F, Lluch P, Escudero A, Rodrigo JM. Clinical evaluation of drug-induced hepatitis. Rev Esp Enferm Dig 2005; 97: 258-265
12. Chan KA, Truman A, Gurwitz JH, Hurley JS, Martinson B, Platt R, Everhart JE, Moseley RH, Terrault N, Ackerson L, Selby JV. A cohort study of the incidence of serious acute liver injury in diabetic patients treated with hypoglycemic agents. Arch Intern Med 2003; 163: 728-734
13. Aithal PG, Day CP. The natural history of histologically proved drug induced liver disease. Gut 1999; 44: 731-735
14. Garcia Rodriguez LA, Ruigomez A, Jick H. A review of epidemiologic research on drug-induced acute liver injury using the general practice research data base in the United Kingdom. Pharmacotherapy 1997; 17: 721-728
15. Li B, Wang Z, Fang JJ, Xu CY, Chen WX. Evaluation of prognostic markers in severe drug-induced liver disease. World J Gastroenterol 2007; 13: 628-632
16. Hussaini SH, Farrington EA. Idiosyncratic drug-induced liver injury: an overview. Expert Opin Drug Saf 2007; 6: 673-684
17. Kaplowitz N. Biochemical and cellular mechanisms of toxic liver injury. Semin Liver Dis 2002; 22: 137-144
18. Masubuchi Y, Suda C, Horie T. Involvement of mitochondrial permeability transition in acetaminophen-induced liver injury in mice. J Hepatol 2005; 42: 110-116
19. Kon K, Ikejima K, Okumura K, Aoyama T, Arai K, Takei Y, Lemasters JJ, Sato N. Role of apoptosis in acetaminophen hepatotoxicity. J Gastroenterol Hepatol 2007; 22 Suppl 1: S49-S52
20. Wang H, LeCluyse EL. Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes. Clin Pharmacokinet 2003; 42: 1331-1357
21. van Gijssel HE, Mullenders LH, van Oosterwijk MF, Meerman JH. Blockage of transcription as a trigger for p53 accumulation by 2-acetylaminofluorene DNA-adducts. Life Sci 2003; 73: 1759-1771
22. Jeong DH, Lee SJ, Lee JH, Bae IH, Jeong KS, Jang JJ, Lim IK, Kim MR, Lee MJ, Lee YS. Subcellular redistribution of protein kinase C isozymes is associated with rat liver cirrhotic changes induced by carbon tetrachloride or thioacetamide. J Gastroenterol Hepatol 2001; 16: 34-40
23. Weber LW, Boll M, Stampfl A. Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model. Crit Rev Toxicol 2003; 33: 105-136
24. Mehal WZ, Azzaroli F, Crispe IN. Immunology of the healthy liver: old questions and new insights. Gastroenterology 2001; 120: 250-260
25. Doherty DG, Norris S, Madrigal-Estebas L, McEntee G, Traynor O, Hegarty JE, O'Farrelly C. The human liver contains multiple populations of NK cells, T cells, and CD3+CD56+ natural T cells with distinct cytotoxic activities and Th1, Th2, and Th0 cytokine secretion patterns. J Immunol 1999; 163: 2314-2321
26. Chen H, Paul WE. Cultured NK1.1+ CD4+ T cells produce large amounts of IL-4 and IFN-gamma upon activation by anti-CD3 or CD1. J Immunol 1997; 159: 2240-2249
27. Li Z, Diehl AM. Innate immunity in the liver. Curr Opin Gastroenterol 2003; 19: 565-571
28. Calne RY, Sells RA, Pena JR, Davis DR, Millard PR, Herbertson BM, Binns RM, Davies DA. Induction of immunological tolerance by porcine liver allografts. Nature 1969; 223: 472-476
29. Klugewitz K, Blumenthal-Barby F, Schrage A, Knolle PA, Hamann A, Crispe IN. Immunomodulatory effects of the liver: deletion of activated CD4+ effector cells and suppression of IFN-gamma-producing cells after intravenous protein immunization. J Immunol 2002; 169: 2407-2413
30. Limmer A, Ohl J, Kurts C, Ljunggren HG, Reiss Y, Groettrup M, Momburg F, Arnold B, Knolle PA. Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance. Nat Med 2000; 6: 1348-1354
31. Castell JV. Allergic hepatitis: a drug-mediated organ-specific immune reaction. Clin Exp Allergy 1998; 28 Suppl 4: 13-19
32. Prandota J. Important role of proinflammatory cytokines/other endogenous substances in drug-induced hepatotoxicity: depression of drug metabolism during infections/inflammation states, and genetic polymorphisms of drug-metabolizing enzymes/cytokines may markedly contribute to this pathology. Am J Ther 2005; 12: 254-261
33. Haouzi D, Lekehal M, Moreau A, Moulis C, Feldmann G, Robin MA, Letteron P, Fau D, Pessayre D. Cytochrome P450-generated reactive metabolites cause mitochondrial permeability transition, caspase activation, and apoptosis in rat hepatocytes. Hepatology 2000; 32: 303-311
34. Critchley JA, Nimmo GR, Gregson CA, Woolhouse NM, Prescott LF. Inter-subject and ethnic differences in paracetamol metabolism. Br J Clin Pharmacol 1986; 22: 649-657
35. Tarantino G, Conca P, Basile V, Gentile A, Capone D, Polichetti G, Leo E. A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease. Hepatol Res 2007; 37: 410-415
36. Parola M, Robino G. Oxidative stress-related molecules and liver fibrosis. J Hepatol 2001; 35: 297-306
37. Arteel GE. Oxidants and antioxidants in alcohol-induced liver disease. Gastroenterology 2003; 124: 778-790
38. Chen Q, Cederbaum AI. Cytotoxicity and apoptosis produced by cytochrome P450 2E1 in Hep G2 cells. Mol Pharmacol 1998; 53: 638-648
39. Konstandi M, Marselos M, Radon-Camus AM, Johnson E, Lang MA. The role of stress in the regulation of drug metabolizing enzymes in mice. Eur J Drug Metab Pharmacokinet 1998; 23: 483-490
40. Murray M. Altered CYP expression and function in response to dietary factors: potential roles in disease pathogenesis. Curr Drug Metab 2006; 7: 67-81
41. Ramaiah SK, Apte U, Mehendale HM. Cytochrome P4502E1 induction increases thioacetamide liver injury in diet-restricted rats. Drug Metab Dispos 2001; 29: 1088-1095
42. Shakya R, Rao BS, Shrestha B. Incidence of hepatotoxicity due to antitubercular medicines and assessment of risk factors. Ann Pharmacother 2004; 38: 1074-1079
43. Eichelbaum M, Kroemer HK, Mikus G. Genetically determined differences in drug metabolism as a risk factor in drug toxicity. Toxicol Lett 1992; 64-65 Spec No: 115-122
44. Chou WH, Yan FX, de Leon J, Barnhill J, Rogers T, Cronin M, Pho M, Xiao V, Ryder TB, Liu WW, Teiling C, Wedlund PJ. Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J Clin Psychopharmacol 2000; 20: 246-251
45. Scott RJ, Palmer J, Lewis IA, Pleasance S. Determination of a 'GW cocktail' of cytochrome P450 probe substrates and their metabolites in plasma and urine using automated solid phase extraction and fast gradient liquid chromatography tandem mass spectrometry. Rapid Commun Mass Spectrom 1999; 13: 2305-2319
46. Yin OQ, Lam SS, Lo CM, Chow MS. Rapid determination of five probe drugs and their metabolites in human plasma and urine by liquid chromatography/tandem mass spectrometry: application to cytochrome P450 phenotyping studies. Rapid Commun Mass Spectrom 2004; 18: 2921-2933
47. Mulder AB, van Lijf HJ, Bon MA, van den Bergh FA, Touw DJ, Neef C, Vermes I. Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin. Clin Pharmacol Ther 2001; 70: 546-551
48. Kirchheiner J, Kudlicz D, Meisel C, Bauer S, Meineke I, Roots I, Brockmoller J. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. Clin Pharmacol Ther 2003; 74: 186-194
49. Pachkoria K, Lucena MI, Ruiz-Cabello F, Crespo E, Cabello MR, Andrade RJ. Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI). Br J Pharmacol 2007; 150: 808-815
50. Eichelbaum M, Evert B. Influence of pharmacogenetics on drug disposition and response. Clin Exp Pharmacol Physiol 1996; 23: 983-985
51. Schwab M, Schaeffeler E, Klotz U, Treiber G. CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori. Clin Pharmacol Ther 2004; 76: 201-209
52. Jia N, Liu X, Wen J, Qian L, Qian X, Wu Y, Fan G. A proteomic method for analysis of CYP450s protein expression changes in carbon tetrachloride induced male rat liver microsomes. Toxicology 2007; 237: 1-11
53. Geubel AP, De Galocsy C, Alves N, Rahier J, Dive C. Liver damage caused by therapeutic vitamin A administration: estimate of dose-related toxicity in 41 cases. Gastroenterology 1991; 100: 1701-1709
54. Lammert C, Einarsson S, Saha C, Niklasson A, Bjornsson E, Chalasani N. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology 2008; 47: 2003-2009
55. Fuhr U. Induction of drug metabolising enzymes: pharmacokinetic and toxicological consequences in humans. Clin Pharmacokinet 2000; 38: 493-504
56. Wang AG, Xia T, Yuan J, Yu RA, Yang KD, Chen XM, Qu W, Waalkes MP. Effects of phenobarbital on metabolism and toxicity of diclofenac sodium in rat hepatocytes in vitro. Food Chem Toxicol 2004; 42: 1647-1653
57. Somchit N, Wong CW, Zuraini A, Ahmad Bustamam A, Hasiah AH, Khairi HM, Sulaiman MR, Israf DA. Involvement of phenobarbital and SKF 525A in the hepatotoxicity of antifungal drugs itraconazole and fluconazole in rats. Drug Chem Toxicol 2006; 29: 237-253
58. Mutlib A, Jiang P, Atherton J, Obert L, Kostrubsky S, Madore S, Nelson S. Identification of potential genomic biomarkers of hepatotoxicity caused by reactive metabolites of N-methylformamide: Application of stable isotope labeled compounds in toxicogenomic studies. Chem Res Toxicol 2006; 19: 1270-1283
59. Chitturi S, George J. Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. Semin Liver Dis 2002; 22: 169-183
60. Russo MW, Jacobson IM. How to use statins in patients with chronic liver disease. Cleve Clin J Med 2004; 71: 58-62
61. Ahn BM. [Herbal preparation-induced liver injury] Korean J Gastroenterol 2004; 44: 113-125
62. Calapai G, Caputi AP. Herbal medicines: can we do without pharmacologist? Evid Based Complement Alternat Med 2007; 4: 41-43
63. Furbee RB, Barlotta KS, Allen MK, Holstege CP. Hepatotoxicity associated with herbal products. Clin Lab Med 2006; 26: 227-241, x
64. Stickel F, Baumuller HM, Seitz K, Vasilakis D, Seitz G, Seitz HK, Schuppan D. Hepatitis induced by Kava (Piper methysticum rhizoma). J Hepatol 2003; 39: 62-67
65. Stickel F, Poschl G, Seitz HK, Waldherr R, Hahn EG, Schuppan D. Acute hepatitis induced by Greater Celandine (Chelidonium majus). Scand J Gastroenterol 2003; 38: 565-568
66. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-245
67. Danan G, Benichou C. Causality assessment of adverse reactions to drugs - I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46: 1323-1330
68. Maria VA, Victorino RM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997; 26: 664-669
69. Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 2003; 163: 2716-2724
70. Olivier P, Caron J, Haramburu F, Imbs JL, Jonville-Bera AP, Lagier G, Sgro C, Vial T, Montastruc JL, Lapeyr-Mestre M. [Validation of a measurement scale: example of a French Adverse Drug Reactions Preventability Scale] Therapie 2005; 60: 39-45
71. Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs - II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993; 46: 1331-1336
72. Arimone Y, Begaud B, Miremont-Salame G, Fourrier-Reglat A, Moore N, Molimard M, Haramburu F. Agreement of expert judgment in causality assessment of adverse drug reactions. Eur J Clin Pharmacol 2005; 61: 169-173
73. Lanctot KL, Naranjo CA. Comparison of the Bayesian approach and a simple algorithm for assessment of adverse drug events. Clin Pharmacol Ther 1995; 58: 692-698
74. Macedo AF, Marques FB, Ribeiro CF, Teixeira F. Causality assessment of adverse drug reactions: comparison of the results obtained from published decisional algorithms and from the evaluations of an expert panel. Pharmacoepidemiol Drug Saf 2005; 14: 885-890
75. Knight A. Systematic reviews of animal experiments demonstrate poor human clinical and toxicological utility. Altern Lab Anim 2007; 35: 641-659
76. Gruber FP, Dewhurst DG. Alternatives to animal experimentation in biomedical education. ALTEX 2004; 21 Suppl 1: 33-48
77. Larson AM. Acetaminophen hepatotoxicity. Clin Liver Dis 2007; 11: 525-548, vi
78. Rumack BH. Acetaminophen hepatotoxicity: the first 35 years. J Toxicol Clin Toxicol 2002; 40: 3-20
79. Brass EP. Hepatic toxicity of antirheumatic drugs. Cleve Clin J Med 1993; 60: 466-472
80. Tanner LA, Bosco LA, Zimmerman HJ. Hepatic toxicity after acebutolol therapy. Ann Intern Med 1989; 111: 533-534
81. Al-Kawas FH, Seeff LB, Berendson RA, Zimmerman HJ, Ishak KG. Allopurinol hepatotoxicity. Report of two cases and review of the literature. Ann Intern Med 1981; 95: 588-590
82. Gawlikowski T, Hydzik P. [Carbamazepine hepatoxicity - a case report] Przegl Lek 2007; 64: 318-319
83. Hashimoto F, Davis RL, Egli D. Hepatitis following treatments with famotidine and then cimetidine. Ann Pharmacother 1994; 28: 37-39
84. Wilkinson SP, Portmann B, Williams R. Hepatitis from dantrolene sodium. Gut 1979; 20: 33-36
85. Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol 2008; 23: 192-202
86. See A, Hervio P, Bouvry M. [The hepatotoxicity of ethionamide remains a topical subject. Apropos of a case of acute hepatitis] Ann Gastroenterol Hepatol (Paris) 1986; 22: 129-130
87. Sinha A, Clatch RJ, Stuck G, Blumenthal SA, Patel SA. Isoflurane hepatotoxicity: a case report and review of the literature. Am J Gastroenterol 1996; 91: 2406-2409
88. Robinson DS, Kurtz NM. What is the degree of risk of hepatotoxicity for depressed patients receiving phenelzine therapy? Is the risk sufficient to require that we modify the written advice (as to diet and risks) that we regularly give our patients before we institute this therapy? J Clin Psychopharmacol 1987; 7: 61-62
89. Portal RW, Emanuel RW. Phenindione hepatitis complicating anticoagulant therapy. Br Med J 1961; 2: 1318-1319
90. Roberts EA, Spielberg SP, Goldbach M, Phillips MJ. Phenobarbital hepatotoxicity in an 8-month-old infant. J Hepatol 1990; 10: 235-239
91. Brackett CC, Bloch JD. Phenytoin as a possible cause of acetaminophen hepatotoxicity: case report and review of the literature. Pharmacotherapy 2000; 20: 229-233
92. Ray DC, Drummond GB. Halothane hepatitis. Br J Anaesth 1991; 67: 84-99
93. Lake-Bakaar G, Scheuer PJ, Sherlock S. Hepatic reactions associated with ketoconazole in the United Kingdom. Br Med J (Clin Res Ed) 1987; 294: 419-422
94. Clark JA, Zimmerman HJ, Tanner LA. Labetalol hepatotoxicity. Ann Intern Med 1990; 113: 210-213
95. Weinstein RP, Gosselin JY. Case report of hepatotoxicity associated with maprotiline. Can J Psychiatry 1988; 33: 233-234
96. Lennard MS. Metoprolol-induced hepatitis: is the rate of oxidation related to drug-induced hepatotoxicity? Hepatology 1989; 9: 163-164
97. Barbare JC, Biour M, Cadot T, Latrive JP. [Hepatotoxicity of mianserin: a case with positive reintroduction] Gastroenterol Clin Biol 1992; 16: 486-488
98. Poli M, Cordie L. [Liver disease caused by PAS: toxic manifestations of PAS.] Arch Sci Med (Torino) 1952; 93: 391-424
99. Handler SD, Hirsch NR, Haas K, Davidson FZ. Quinidine hepatitis. Arch Intern Med 1975; 135: 871-872
100. Larrey D, Vial T, Micaleff A, Babany G, Morichau-Beauchant M, Michel H, Benhamou JP. Hepatitis associated with amoxycillin-clavulanic acid combination report of 15 cases. Gut 1992; 33: 368-371
101. Ribeiro JM, Lucas M, Baptista A, Victorino RM. Fatal hepatitis associated with ranitidine. Am J Gastroenterol 2000; 95: 559-560
102. Mainra RR, Card SE. Trimethoprim-sulfamethoxazole-associated hepatotoxicity - part of a hypersensitivity syndrome. Can J Clin Pharmacol 2003; 10: 175-178
103. Lucena MI, Carvajal A, Andrade RJ, Velasco A. Antidepressant-induced hepatotoxicity. Expert Opin Drug Saf 2003; 2: 249-262
104. Zaman F, Ye G, Abreo KD, Latif S, Zibari GB. Successful orthotopic liver transplantation after trimethoprim-sulfamethoxazole associated fulminant liver failure. Clin Transplant 2003; 17: 461-464
105. Tennison MB, Miles MV, Pollack GM, Thorn MD, Dupuis RE. Valproate metabolites and hepatotoxicity in an epileptic population. Epilepsia 1988; 29: 543-547
106. Odeh M, Oliven A. [Verapamil-associated liver injury] Harefuah 1998; 134: 36-37
107. Dourakis SP, Sevastianos VA, Kaliopi P. Acute severe steatohepatitis related to prednisolone therapy. Am J Gastroenterol 2002; 97: 1074-1075
108. de Leval L, Lambermont B, D'Orio V, Boniver J. Fatal massive liver steatosis - a clinicopathological case report. Acta Gastroenterol Belg 1997; 60: 180-183
109. Berson A, De Beco V, Letteron P, Robin MA, Moreau C, El Kahwaji J, Verthier N, Feldmann G, Fromenty B, Pessayre D. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology 1998; 114: 764-774
110. Pratt CB, Johnson WW. Duration and severity of fatty metamorphosis of the liver following L-asparaginase therapy. Cancer 1971; 28: 361-364
111. Gradon JD, Sepkowitz DV. Massive hepatic enlargement with fatty change associated with ketoconazole. DICP 1990; 24: 1175-1176
112. Arranto AJ, Sotaniemi EA. Morphologic alterations in patients with alpha-methyldopa-induced liver damage after short- and long-term exposure. Scand J Gastroenterol 1981; 16: 853-863
113. Babany G, Uzzan F, Larrey D, Degott C, Bourgeois P, Rene E, Vissuzaine C, Erlinger S, Benhamou JP. Alcoholic-like liver lesions induced by nifedipine. J Hepatol 1989; 9: 252-255
114. Deschamps D, DeBeco V, Fisch C, Fromenty B, Guillouzo A, Pessayre D. Inhibition by perhexiline of oxidative phosphorylation and the beta-oxidation of fatty acids: possible role in pseudoalcoholic liver lesions. Hepatology 1994; 19: 948-961
115. Wenk RE, Gebhardt FC, Bhagavan BS, Lustgarten JA, Mc-Carthy EF. Tetracycline-associated fatty liver of pregnancy, including possible pregnancy risk after chronic dermatologic use of tetracycline. J Reprod Med 1981; 26: 135-141
116. Walia KS, Khan EA, Ko DH, Raza SS, Khan YN. Side effects of antiepileptics - a review. Pain Pract 2004; 4: 194-203
117. Bienvenu L, Burel F, Hofman V, Itchai C, Amaro J, Hofman P. [A rare etiology of hepatic steatosis associated with lactic acidosis: the toxicity of antiviral nucleoside analogues] Ann Pathol 2001; 21: 160-163
118. Alexander P, Roskams T, Van Steenbergen W, Peetermans W, Desmet V, Yap SH. Intrahepatic cholestasis induced by amoxicillin/clavulanic acid (Augmentin): a report on two cases. Acta Clin Belg 1991; 46: 327-332
119. Eisenbach C, Goeggelmann C, Flechtenmacher C, Stremmel W, Encke J. Severe cholestatic hepatitis caused by azathioprine. Immunopharmacol Immunotoxicol 2005; 27: 77-83
120. Schattner A, Kozak N, Friedman J. Captopril-induced jaundice: report of 2 cases and a review of 13 additional reports in the literature. Am J Med Sci 2001; 322: 236-240
121. Larrey D, Hadengue A, Pessayre D, Choudat L, DeGott C, Benhamou JP. Carbamazepine-induced acute cholangitis. Dig Dis Sci 1987; 32: 554-557
122. Chan AO, Ng IO, Lam CM, Shek TW, Lai CL. Cholestatic jaundice caused by sequential carbimazole and propylthiouracil treatment for thyrotoxicosis. Hong Kong Med J 2003; 9: 377-380
123. Skoog SM, Smyrk TC, Talwalkar JA. Cephalexin-induced cholestatic hepatitis. J Clin Gastroenterol 2004; 38: 833
124. Lo KJ, Eastwood IR, Eidelman S. Cholestatic jaundice associated with chlordiazepoxide hydrochloride (Librium) therapy. Report of a case and review of the literature. Am J Dig Dis 1967; 12: 845-849
125. Gupta R, Sachar DB. Chlorpropamide-induced cholestatic jaundice and pseudomembranous colitis. Am J Gastroenterol 1985; 80: 381-383
126. Lotric S, Lejko-Zupanc T, Jereb M. Cloxacillin-induced cholestasis. Clin Infect Dis 1994; 19: 981-982
127. Day C, Hewins P, Sheikh L, Kilby M, McPake D, Lipkin G. Cholestasis in pregnancy associated with ciclosporin therapy in renal transplant recipients. Transpl Int 2006; 19: 1026-1029
128. Silva MO, Reddy KR, McDonald T, Jeffers LJ, Schiff ER. Danazol-induced cholestasis. Am J Gastroenterol 1989; 84: 426-428
129. Bakris GL, Cross PD, Hammarsten JE. Disopyramide-associated liver dysfunction. Mayo Clin Proc 1983; 58: 265-267
130. Todd P, Levison D, Farthing MJ. Enalapril-related cholestatic jaundice. J R Soc Med 1990; 83: 271-272
131. Derby LE, Jick H, Henry DA, Dean AD. Erythromycin-associated cholestatic hepatitis. Med J Aust 1993; 158: 600-602
132. Devereaux BM, Crawford DH, Purcell P, Powell LW, Roeser HP. Flucloxacillin associated cholestatic hepatitis. An Australian and Swedish epidemic? Eur J Clin Pharmacol 1995; 49: 81-85
133. Reynolds R, Lloyd DA, Slinger RP. Cholestatic jaundice induced by flurazepam hydrochloride. Can Med Assoc J 1981; 124: 893-894
134. Lee HW, Chung JP, Lee KS, Kim KC, Lee KS, Chon CY, Park IS, Kim HG. A case of flutamide-induced acute cholestatic hepatitis - a case report. Yonsei Med J 1996; 37: 225-229
135. Basset C, Vadrot J, Denis J, Poupon J, Zafrani ES. Prolonged cholestasis and ductopenia following gold salt therapy. Liver Int 2003; 23: 89-93
136. Chiprut RO, Viteri A, Jamroz C, Dyck WP. Intrahepatic cholestasis after griseofulvin administration. Gastroenterology 1976; 70: 1141-1143
137. van Basten JP, van Hoek B, Zeijen R, Stockbrugger R. Glyburide-induced cholestatic hepatitis and liver failure. Case-report and review of the literature. Neth J Med 1992; 40: 305-307
138. Horst DA, Grace ND, LeCompte PM. Prolonged cholestasis and progressive hepatic fibrosis following imipramine therapy. Gastroenterology 1980; 79: 550-554
139. Dincsoy HP, Saelinger DA. H aloperidol-induced chronic cholestatic liver disease. Gastroenterology 1982; 83: 694-700
140. Benson GD, Anderson PK, Combes B, Ishak KG. Prolonged jaundice following ketoconazole-induced hepatic injury. Dig Dis Sci 1988; 33: 240-246
141. Foitl DR, Hyman G, Lefkowitch JH. Jaundice and intrahepatic cholestasis following high-dose megestrol acetate for breast cancer. Cancer 1989; 63: 438-439
142. Schmidt G, Borsch G, Muller KM, Wegener M. Methimazole-associated cholestatic liver injury: case report and brief literature review. Hepatogastroenterology 1986; 33: 244-246
143. Lucey MR, Moseley RH. Severe cholestasis associated with methyltestosterone: a case report. Am J Gastroenterol 1987; 82: 461-462
144. Kiire CF, Rutherford D. Nifedipine-associated jaundice: a second case. East Afr Med J 1986; 63: 560-561
145. Mulberg AE, Bell LM. Fatal cholestatic hepatitis and multi-system failure associated with nitrofurantoin. J Pediatr Gastroenterol Nutr 1993; 17: 307-309
146. Gilbert EF, Dasilva AQ, Queen DM. Intrahepatic cholestasis with fatal termination following norethandrolone therapy. JAMA 1963; 185: 538-539
147. Lieberman DA, Keeffe EB, Stenzel P. Severe and prolonged oral contraceptive jaundice. J Clin Gastroenterol 1984; 6: 145-148
148. Moradpour D, Altorfer J, Flury R, Greminger P, Meyenberger C, Jost R, Schmid M. Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis. Hepatology 1994; 20: 1437-1441
149. Altuntas Y, Ozturk B, Erdem L, Gunes G, Karul S, Ucak S, Sengul A. Phenytoin-induced toxic cholestatic hepatitis in a patient with skin lesions: case report. South Med J 2003; 96: 201-203
150. Gefel D, Harats N, Lijovetsky G, Eliakim M. Cholestatic jaundice associated with D-penicillamine therapy. Scand J Rheumatol 1985; 14: 303-306
151. Rosenberg WM, Ryley NG, Trowell JM, McGee JO, Chapman RW. Dextropropoxyphene induced hepatotoxicity: a report of nine cases. J Hepatol 1993; 19: 470-474
152. Kouklakis G, Mpoumponaris A, Zezos P, Moschos J, Koulaouzidis A, Nakos A, Pehlivanidis A, Iosiphidis M, Molyvas E, Nikolaidis N. Cholestatic hepatitis with severe systemic reactions induced by trimethoprim-sulfamethoxazole. Ann Hepatol 2007; 6: 63-65
153. Lasso De La Vega MC, Zapater P, Such J, Sola-Vera J, Paya A, Horga JF, Perez-Mateo M. [Toxic hepatitis associated with tamoxifen use. A case report and literature review] Gastroenterol Hepatol 2002; 25: 247-250
154. Eland IA, Kerkhof SC, Overbosch D, Wismans PJ, Stricker BH. [Cholestatic hepatitis ascribed to the use of thiabendazole] Ned Tijdschr Geneeskd 1998; 142: 1331-1334
155. Nakao NL, Gelb AM, Stenger RJ, Siegel JH. A case of chronic liver disease due to tolazamide. Gastroenterology 1985; 89: 192-195
156. Randeva HS, Bangar V, Sailesh S, Hillhouse EW. Fatal cholestatic jaundice associated with amitriptyline. Int J Clin Pract 2000; 54: 405-406
157. Larrey D, Amouyal G, Danan G, Degott C, Pessayre D, Benhamou JP. Prolonged cholestasis after troleandomycin-induced acute hepatitis. J Hepatol 1987; 4: 327-329
158. Burgunder JM, Abernethy DR, Lauterburg BH. Liver injury due to verapamil. Hepatogastroenterology 1988; 35: 169-170
159. Vanderstigel M, Zafrani ES, Lejonc JL, Schaeffer A, Portos JL. Allopurinol hypersensitivity syndrome as a cause of hepatic fibrin-ring granulomas. Gastroenterology 1986; 90: 188-190
160. Levy M, Goodman MW, Van Dyne BJ, Sumner HW. Granulomatous hepatitis secondary to carbamazepine. Ann Intern Med 1981; 95: 64-65
161. Ben-Yehuda A, Bloom A, Lijovetzky G, Flusser D, Tur-Kaspa R. Chlorpromazine-induced liver and bone marrow granulomas associated with agranulocytosis. Isr J Med Sci 1990; 26: 449-451
162. Sarachek NS, London RL, Matulewicz TJ. Diltiazem and granulomatous hepatitis. Gastroenterology 1985; 88: 1260-1262
163. Harats N, Ehrenfeld M, Shalit M, Lijovetzky G. Gold-induced granulomatous hepatitis. Isr J Med Sci 1985; 21: 753-756
164. Jori GP, Peschile C. Hydralazine disease associated with transient granulomas in the liver. A case report. Gastroenterology 1973; 64: 1163-1167
165. Sippel PJ, Agger WA. Nitrofurantoin-induced granulomatous hepatitis. Urology 1981; 18: 177-178
166. Silvain C, Fort E, Levillain P, Labat-Labourdette J, Beauchant M. Granulomatous hepatitis due to combination of amoxicillin and clavulanic acid. Dig Dis Sci 1992; 37: 150-152
167. Cook IF, Shilkin KB, Reed WD. Phenytoin induced granulomatous hepatitis. Aust N Z J Med 1981; 11: 539-541
168. Knobel B, Buyanowsky G, Dan M, Zaidel L. Pyrazinamide-induced granulomatous hepatitis. J Clin Gastroenterol 1997; 24: 264-266
169. Bramlet DA, Posalaky Z, Olson R. Granulomatous hepatitis as a manifestation of quinidine hypersensitivity. Arch Intern Med 1980; 140: 395-397
170. Namias A, Bhalotra R, Donowitz M. Reversible sulfasalazine-induced granulomatous hepatitis. J Clin Gastroenterol 1981; 3: 193-198
171. Seeff LB. Drug-induced chronic liver disease, with emphasis on chronic active hepatitis. Semin Liver Dis 1981; 1: 104-115
172. Black M, Mitchell JR, Zimmerman HJ, Ishak KG, Epler GR. Isoniazid-associated hepatitis in 114 patients. Gastroenterology 1975; 69: 289-302
173. Balazs M, Kovach G. Chronic aggressive hepatitis after methyldopa treatment. Case report with electron-microscopic study. Hepatogastroenterology 1981; 28: 199-202
174. Roy AK, Mahoney HC, Levine RA. Phenytoin-induced chronic hepatitis. Dig Dis Sci 1993; 38: 740-743
175. Aponte J, Petrelli M. Histopathologic findings in the liver of rheumatoid arthritis patients treated with long-term bolus methotrexate. Arthritis Rheum 1988; 31: 1457-1464
176. Volbeda F, Jonker AM, Vecht J, Groeneveld PH. [Liver cirrhosis due to chronic use of nitrofurantoin] Ned Tijdschr Geneeskd 2004; 148: 235-238
177. Anania FA, Rabin L. Terbinafine hepatotoxicity resulting in chronic biliary ductopenia and portal fibrosis. Am J Med 2002; 112: 741-742
178. Giannitrapani L, Soresi M, La Spada E, Cervello M, D'Alessandro N, Montalto G. Sex hormones and risk of liver tumor. Ann N Y Acad Sci 2006; 1089: 228-236
179. Bartley J, Loddenkemper C, Lange J, Mechsner S, Radke C, Neuhaus P, Ebert AD. Hepatocellular adenoma and focal nodular hyperplasia after long-term use of danazol for endometriosis: a case report. Arch Gynecol Obstet 2004; 269: 290-293
180. Zhu AX, Lauwers GY, Tanabe KK. Cholangiocarcinoma in association with Thorotrast exposure. J Hepatobiliary Pancreat Surg 2004; 11: 430-433
181. Chopra S, Edelstein A, Koff RS, Zimelman AP, Lacson A, Neiman RS. Peliosis hepatis in hematologic disease. Report of two cases. JAMA 1978; 240: 1153-1155
182. Sebagh M, Debette M, Samuel D, Emile JF, Falissard B, Cailliez V, Shouval D, Bismuth H, Reynes M. "Silent" presentation of veno-occlusive disease after liver transplantation as part of the process of cellular rejection with endothelial predilection. Hepatology 1999; 30: 1144-1150
183. Essell JH, Thompson JM, Harman GS, Halvorson RD, Snyder MJ, Johnson RA, Rubinsak JR. Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/cyclophosphamide. Blood 1992; 79: 2784-2788
184. Voigt H, Caselitz J, Janner M. [Veno-occlusive syndrome with acute liver dystrophy following decarbazine therapy of malignant melanoma (author's transl)] Klin Wochenschr 1981; 59: 229-236
185. Spormann H, Willgeroth C, Tautenhahn P. [Peliosis hepatis with liver rupture] Zentralbl Allg Pathol 1985; 130: 545-550
186. Lennard L, Richards S, Cartwright CS, Mitchell C, Lilleyman JS, Vora A. The thiopurine methyltransferase genetic polymorphism is associated with thioguanine-related veno-occlusive disease of the liver in children with acute lymphoblastic leukemia. Clin Pharmacol Ther 2006; 80: 375-383
187. Sulis ML, Bessmertny O, Granowetter L, Weiner M, Kelly KM. Veno-occlusive disease in pediatric patients receiving actinomycin D and vincristine only for the treatment of rhabdomyosarcoma. J Pediatr Hematol Oncol 2004; 26: 843-846
188. Ouellet G, Tremblay L, Marleau D. Fulminant hepatitis induced by lamotrigine. South Med J 2009; 102: 82-84
189. Tan HH, Ong WM, Lai SH, Chow WC. Nimesulide-induced hepatotoxicity and fatal hepatic failure. Singapore Med J 2007; 48: 582-585
190. Skopp G, Schmitt HP, Pedal I. [Fulminant liver failure in a patient on carbamazepine and levetiracetam treatment associated with status epilepticus] Arch Kriminol 2006; 217: 161-175
191. Barcena R, Oton E, Angeles Moreno M, Fortun J, Garcia-Gonzalez M, Moreno A, de Vicente E. Is liver transplantation advisable for isoniazid fulminant hepatitis in active extrapulmonary tuberculosis? Am J Transplant 2005; 5: 2796-2798
192. Tietz A, Heim MH, Eriksson U, Marsch S, Terracciano L, Krahenbuhl S. Fulminant liver failure associated with clarithromycin. Ann Pharmacother 2003; 37: 57-60
193. Garbino J, Henry JA, Mentha G, Romand JA. Ecstasy ingestion and fulminant hepatic failure: liver transplantation to be considered as a last therapeutic option. Vet Hum Toxicol 2001; 43: 99-102
194. Stickel F, Egerer G, Seitz HK. Hepatotoxicity of botanicals. Public Health Nutr 2000; 3: 113-124
195. Gordon DW, Rosenthal G, Hart J, Sirota R, Baker AL. Chaparral ingestion. The broadening spectrum of liver injury caused by herbal medications. JAMA 1995; 273: 489-490
196. Russmann S, Lauterburg BH, Helbling A. Kava hepatotoxicity. Ann Intern Med 2001; 135: 68-69
197. Lee MK, Cheng BW, Che CT, Hsieh DP. Cytotoxicity assessment of Ma-huang (Ephedra) under different conditions of preparation. Toxicol Sci 2000; 56: 424-430
198. Whiting PW, Clouston A, Kerlin P. Black cohosh and other herbal remedies associated with acute hepatitis. Med J Aust 2002; 177: 440-443
199. Lake CR, Gallant S, Masson E, Miller P. Adverse drug effects attributed to phenylpropanolamine: a review of 142 case reports. Am J Med 1990; 89: 195-208
200. Sanchez W, Maple JT, Burgart LJ, Kamath PS. Severe hepatotoxicity associated with use of a dietary supplement containing usnic acid. Mayo Clin Proc 2006; 81: 541-544
201. Bleibel W, Kim S, D'Silva K, Lemmer ER. Drug-induced liver injury: review article. Dig Dis Sci 2007; 52: 2463-2471